ClinicalTrials.gg
RecruitingNCT06267105Updated Oct 21, 2026

A Clinical Study to Compare Functional Outcomes After Surgery Using a Transverse or Longitudinal Surgical Incision in the Skin.

An interventional study of Longitudinal incision and Transverse incision in Functional Disturbance as Result, sponsored by Corporacion Parc Tauli. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Corporacion Parc Tauli · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Trigger finger is a common pathology in the hand. Patients suffer from pain and depending on which tasks, patients have difficulty to perform them. Its treatment in initial and less serious phases includes conservative measures, but failure of these may require releasing the trigger finger with surgery. The surgical technique performed for trigger finger is the opening of the A1 pulley, the skin incisions used for this surgery are various (transverse, longitudinal, oblique). Trigger finger surgery presents good results in terms of resolution, but complications may also occur. The reason for this study is to assess whether there are functional differences using the Dash scale when we perform a transverse or longitudinal incision in trigger finger surgery.

02

Conditions studied

  • Functional Disturbance as Result
03

In context

Lead sponsor

Corporacion Parc Tauli is the lead sponsor of 167 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age.
  • Clinical diagnosis of trigger finger grade II to IV.

Grade I (pre-trigger) Pain, history of entrapment, but not demonstrable on physical examination, tenderness over the A1 pulley.

Grade II (active) Demonstrable entrapment, but the patient can actively extend the finger.

Grade III (passive) Demonstrable entrapment, patient requires passive extension IIIA or inability to actively flex IIIB.

Grade IV (contracture) Demonstrable entrapment with fixed flexion contracture of the PIP.

Exclusion criteria

Exclusion Criteria:

  • Thumb
  • Polydigital
  • Allergy to local anesthetics and/or vasoconstrictor agents.
  • Previous surgery
  • Patients who, in the researcher's opinion, are not good candidates for the study (e.g. inability to comply with the follow-up program, comorbidity, poor physical or mental health in general, drug or alcohol abuse problems...).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Longitudinal incision

    Incision performed longitudinally

    Procedure: Longitudinal incision

  • Experimental
    Transverse incision

    Incision performed transversally

    Procedure: Transverse incision

Interventions

  • ProcedureLongitudinal incision

    Incision performed longitudinally

  • ProcedureTransverse incision

    Incision performed transversally

06

What researchers measure

Primary outcomes

  1. Functional improvement of the patient after surgery

    functional improvement of the patient after surgery, which will be assessed with the Dash scale, 1 being difficult while 5 being unable

    Time frame: Immediately after surgery

Secondary outcomes

  1. Surgeon comfort

    Ecellent, good, poor

    Time frame: Immediately after surgery

  2. Resolution

    Presence or absence of engagment

    Time frame: 1, 3 and 6 months

  3. Flushed

    Red or not red

    Time frame: 1, 3 and 6 months

  4. Pain feeling

    EVA scale from 0 to 10, being 10 a lot of pain

    Time frame: 1, 3 and 6 months

  5. Contracture

    Range of motion in degrees

    Time frame: 1, 3 and 6 months

  6. Infection

    Septic signs such the area is red, hot, swelling or has drain pus

    Time frame: 1, 3 and 6 months

  7. Nerve injury

    Allen test to evaluate correct circulation, the hand should turn white when pressing

    Time frame: 1, 3 and 6 months

  8. Return to work

    How many weeks after surgery

    Time frame: 1, 3 and 6 months

  9. Reincorporation to activities

    How many weeks after surgery

    Time frame: 1, 3 and 6 months

  10. Sensitivity Test

    In a scale from 0 to 10

    Time frame: 1, 3 and 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mohd Rashid MZ, Sapuan J, Abdullah S. A randomized controlled trial of trigger finger release under digital anesthesia with (WALANT) and without adrenaline. J Orthop Surg (Hong Kong). 2019 Jan-Apr;27(1):2309499019833002. doi: 10.1177/2309499019833002. PubMed 30852960 ↗
  • Kazmers NH, Holt D, Tyser AR, Wang A, Hutchinson DT. A prospective, randomized clinical trial of transverse versus longitudinal incisions for trigger finger release. J Hand Surg Eur Vol. 2019 Oct;44(8):810-815. doi: 10.1177/1753193419859375. Epub 2019 Jul 4. PubMed 31272265 ↗
  • Kloeters O, Ulrich DJ, Bloemsma G, van Houdt CI. Comparison of three different incision techniques in A1 pulley release on scar tissue formation and postoperative rehabilitation. Arch Orthop Trauma Surg. 2016 May;136(5):731-7. doi: 10.1007/s00402-016-2430-z. Epub 2016 Feb 29. PubMed 26926477 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for Oct 2027, 41 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Feb 2025 → Oct 2027 and completion Mar 2025 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 20, 2024
StartActual
May 15, 2024
Primary completionEst.
Oct 2027was Feb 2025
CompletionEst.
Mar 2028was Mar 2025
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 2025→Oct 2027
Oct 21, 2026
Study completion
Mar 2025→Mar 2028
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Feb 2025→Oct 2027
    Study completion Mar 2025→Mar 2028
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06267105
Responsible party
Corona Poy (Doctor, Corporacion Parc Tauli) — Principal investigator
First posted
Feb 20, 2024
Start date
May 15, 2024
Primary completion
Oct 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Mireia Vinas
Contact
mmvinas@tauli.cat
+34 93 723 10 10 ext. 21652

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion